CPO assay gets CE mark, 3/18
March 2018—Becton Dickinson and Check-Points obtained the CE mark for a next-generation molecular screening test for antibiotic-resistant carbapenemase-producing organisms on the BD Max System.
Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2018—Becton Dickinson and Check-Points obtained the CE mark for a next-generation molecular screening test for antibiotic-resistant carbapenemase-producing organisms on the BD Max System.
March 2018—Fabric Genomics announced its expanded somatic cancer solution at the 2017 Association for Molecular Pathology annual meeting in November. The solution provides genomic analysis and clinical reporting to clinical labs and enables therapy matching for cancer patients, giving clinicians targeted treatment choices. It offers one integrated platform for the interpretation of somatic cancer panels, hereditary panels, and whole genomes.
March 2018—Quidel has received clearance from the FDA to market its Solana respiratory syncytial virus plus human metapneumovirus assay for the detection of nucleic acids isolated from nasal and nasopharyngeal swabs from patients with signs and symptoms of respiratory infection to aid in the diagnosis of RSV and/or hMPV infections.
March 2018—Roche Diagnostics has introduced the biotinfacts.roche.com website to provide laboratorians with up-to-date data on and best practices for biotin interference. The website offers laboratorians information and answers needed to mitigate risk and help ensure patient safety.
February 2018—SpeeDx announced it has received CE-IVD marking for its PlexPCR VHS multiplex qPCR test. The test offers a single-well solution to cover the detection and differentiation of the main causes of genital and oral lesions—herpes simplex virus types 1 and 2, Treponema pallidum (syphilis), and varicella zoster virus.
February 2018—Sygnis, based in Heidelberg, Germany, announced the launch of its TruePrime Apoptotic Cell-Free DNA Amplification Kit, under its Expedeon brand. The kit enables accurate DNA amplification using cfDNA obtained from plasma, serum, urine, cerebrospinal fluid, and other bodily fluids.
February 2018—MilliporeSigma launched the Stericup Quick Release 500 mL vacuum filtration system, a filter bottle system for sterile filtration of cell culture media, buffers, and reagents.
February 2018—Thermo Fisher Scientific released its MagMax DNA Multi-Sample Ultra 2.0 reagents, which provide genetic testing companies, labs, and service providers with high-throughput DNA extraction from blood, saliva, buffy coat, and buccal swabs. The next-generation reagents can purify DNA from 96 samples in 45 minutes on Thermo Scientific KingFisher instruments using a simplified protocol for either small- or large-volume sample input.
February 2018—Spot Imaging introduced its CytoXpress, an FDA-approved consultation method that lets clinicians and technologists transmit a live, interactive image stream directly to the user’s computer, eliminating the travel and wait time associated with on-site consults.
February 2018—Vector Laboratories introduced the TrueView Autofluorescence Quenching Kit for removing unwanted fluorescence in formalin-fixed, paraffin-embedded tissue samples, blood cells, and structural elements such as collagen and elastin.